STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
LinkMed’s (STO:LMED) portfolio company ONCOlog Medical and the medtech company C-RAD have entered into a strategic agreement in the area of radiotherapy. Under the terms of the agreement the companies will, in the initial stages of the agreement, adapt their patient positioning systems to each other.
When receiving radiotherapy, patients need to be correctly positioned in order to maximize radiation to the tumor and minimize damage to the surrounding tissue. Currently, new advanced radiotherapy techniques, such as intensity-modulated radiation therapy, image-guided radiation therapy (IGRT), adaptive radiation therapy and ionizing radiation therapy, are being developed. These new techniques make it possible to focus the radiotherapy to a defined area, which puts further requirements on the exact positioning of the patient.
The two Swedish companies, ONCOlog Medical and C-RAD, offer technical solutions that quickly and exactly position patients and thereafter monitor the positioning during treatment. The aim of their strategic collaboration is, in its initial stages, to minimize the need for CT/MR-simulation before radiotherapy, as well as for individual fixation equipment. The collaboration facilitates new and efficient solutions that combine ONCOlog Medical’s PatLog Load and SteroLog with C-RAD’s Sentinel.
“The companies’ complementing products for patient positioning ensures safer and more efficient radiation therapy, something that is high on the agenda at radiation clinics all over the world,” says ONCOlog Medical’s CEO, Hans Dahlin.
“ONCOlog Medical’s focus is to develop solutions that make radiotherapy more effective. With this agreement, ONCOlog Medical continues to be a leader in tomorrow’s cancer therapy,” says LinkMed’s CEO, Ingemar Lagerlöf.
LinkMed owns 48 percent of ONCOlog Medical. ONCOlog Medical develops, produces and markets a number of products and system solutions for quality assurance of radiotherapy treatment clinics for cancer.
LinkMed develops new life-science companies in collaboration with innovators. By contributing entrepreneurship and capital, LinkMed has created a portfolio of twelve companies, six in drug development and biotechnology and six in medical technology. The LinkMed share is listed on the OMX Nordic Exchange, Stockholm, and the company’s largest shareholders are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.
This information was brought to you by Cision http://newsroom.cision.com
Contact:
LinkMed Ingemar Lagerlöf, CEO, +46 8 508 939 93
Source: LinkMed
